Sign in

Alzheimer disease: trials that stopped early

Trials on Alzheimer disease that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

86 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population

    Reason given in the registry

    “Due to time and funding constraints, recruitment for the cross-over phase closed before enrolling the planned 500 participants, and the longitudinal phase was not initiated. Not related to participant safety.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Nov 2026.

    Ended
    Dec 2025
    Run by
    Bitbrain
    Registry record
    NCT06993207
  2. Suspended

    Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language

    Reason given in the registry

    “Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Oct 2026.

    Run by
    Poitiers University Hospital
    Registry record
    NCT06902753
  3. Terminated

    Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.

    Reason given in the registry

    “recruitment challenges”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Oct 2026.

    Ended
    Aug 2026
    Run by
    Centre Hospitalier Universitaire de Nice
    Registry record
    NCT06523296
  4. Terminated

    Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

    Reason given in the registry

    “Lack of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.

    Ended
    Sept 2025
    Run by
    Johns Hopkins University
    Registry record
    NCT05978804
  5. Withdrawn

    GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

    Reason given in the registry

    “poor accrual and funding issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2026.

    Ended
    Jun 2026
    Run by
    West China Hospital
    Registry record
    NCT07677865
  6. Suspended

    A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

    Reason given in the registry

    “Administrative”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Sept 2026.

    Run by
    ProgenaBiome
    Registry record
    NCT04031469
  7. Withdrawn

    DECIDE: Dyads and Families

    Reason given in the registry

    “No participants were enrolled in the clinical trial portion. The community-engaged nature of the project required more time than anticipated, and funding was insufficient to support the implementation of the proposed intervention.”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.

    Run by
    Emory University
    Registry record
    NCT05139290
  8. Withdrawn

    Implementation of AIP Services for Older Adults With AD

    Reason given in the registry

    “Not a clinical trial so retiring ClinicalTrials.gov record”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Sept 2026.

    Run by
    Northwestern University
    Registry record
    NCT07361601
  9. Terminated

    The Ketogenic Diet for Alzheimer's Disease

    Reason given in the registry

    “lake of inclusions”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.

    Ended
    Sept 2026
    Run by
    Assistance Publique - Hôpitaux de Paris
    Registry record
    NCT04701957
  10. Withdrawn

    REVERSE-Long COVID-19 With Baricitinib Study

    Reason given in the registry

    “This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Sept 2026.

    Phase
    Phase 3
    Run by
    Vanderbilt University Medical Center
    Registry record
    NCT05858515
  11. Terminated

    Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

    Reason given in the registry

    “Treatment with 20 mg piromelatine did not demonstrate efficacy over treatment with placebo based on analysis with the ADAS-Cog 14 subscale and with other cognitive and neuropsychiatric parameters.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Sept 2026.

    Ended
    Dec 2024
    Phase
    Phase 2/3
    Run by
    Neurim Pharmaceuticals Ltd.
    Registry record
    NCT05267535
  12. Terminated

    Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

    Reason given in the registry

    “Sponsor business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2026.

    Ended
    Mar 2026
    Phase
    Phase 3
    Run by
    Alzheon Inc.
    Registry record
    NCT06304883
  13. Terminated

    An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

    Reason given in the registry

    “Study AXS-05-AD-305 was terminated due to completion of overall program objectives.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2026.

    Ended
    Apr 2025
    Phase
    Phase 3
    Run by
    Axsome Therapeutics, Inc.
    Registry record
    NCT06736509
  14. Terminated

    Implement and Test Visual Consent Template and Process

    Reason given in the registry

    “Insufficient funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2026.

    Ended
    Apr 2026
    Run by
    Washington University School of Medicine
    Registry record
    NCT06804837
  15. Terminated

    Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

    Reason given in the registry

    “Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 May 2026.

    Ended
    Jan 2026
    Phase
    Phase 2
    Run by
    Shanghai Hengrui Pharmaceutical Co., Ltd.
    Registry record
    NCT06199037
  16. Terminated

    Integration of Health Information Technology and Promotion of Personhood in Family-Centered Dementia Care

    Reason given in the registry

    “low enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 May 2026.

    Ended
    Sept 2025
    Run by
    Florida International University
    Registry record
    NCT04571502
  17. Terminated

    A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

    Reason given in the registry

    “Resource Constraints”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 May 2026.

    Ended
    Nov 2023
    Phase
    Phase 2
    Run by
    TrueBinding, Inc.
    Registry record
    NCT05476783
  18. Terminated

    A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

    Reason given in the registry

    “Study discontinued due to sponsor transition and strategic decision not to continue the protocol.”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Apr 2026.

    Ended
    Jan 2026
    Phase
    Phase 1
    Run by
    Alzheimer's Disease Expert Lab (ADEL), Inc.
    Registry record
    NCT06247345
  19. Terminated

    Decision Making Tool for Firearm Storage

    Reason given in the registry

    “Recruitment to the study was determined to not be feasible”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Apr 2026.

    Ended
    Oct 2024
    Run by
    University of Washington
    Registry record
    NCT06382194
  20. Terminated

    Detecting Beta-amyloid in the Retina

    Reason given in the registry

    “This study has been transferred to the Human Research Ethics Committee of St Vincent's Hospital Melbourne.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Apr 2026.

    Ended
    Jan 2024
    Run by
    Center for Eye Research Australia
    Registry record
    NCT07529912
  21. Withdrawn

    Virtual Communication in the Hospital: Impact on Patients and Surrogates

    Reason given in the registry

    “Recruitment effort yielded no enrollments, so this study was stopped. We are re-evaluating the study design.”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Apr 2026.

    Run by
    Indiana University
    Registry record
    NCT05395039
  22. Terminated

    A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

    Reason given in the registry

    “Company will improve study desig”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2026.

    Ended
    Sept 2025
    Phase
    Phase 2
    Run by
    NeuroSense Therapeutics Ltd.
    Registry record
    NCT06185543
  23. Suspended

    The Dose Finding Study of DAOIB Added to tDCS for AD

    Reason given in the registry

    “The trial was suspended due to the budget issue”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Mar 2026.

    Phase
    Phase 2
    Run by
    Chang Gung Memorial Hospital
    Registry record
    NCT05006781
  24. Terminated

    Autonomous Navigating Robot for Detecting Falls and Risk of Falls in Nursing Home Residents With Alzheimer Disease/ADRD - Feasibility Study

    Reason given in the registry

    “The robot had technical problems which couldn't be fixed and the study could not begin.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Mar 2026.

    Ended
    Aug 2025
    Run by
    Vigorous Mind, Inc.
    Registry record
    NCT07451223
  25. Terminated

    An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

    Reason given in the registry

    “Sponsor resource allocation”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Feb 2026.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    Inmune Bio, Inc.
    Registry record
    NCT05522387
  26. Terminated

    A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

    Reason given in the registry

    “Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Feb 2026.

    Ended
    Feb 2025
    Phase
    Phase 2
    Run by
    Alector Inc.
    Registry record
    NCT05744401
  27. Suspended

    Risk Screening & Primary Prevention of Elder Abuse in People Living With Dementia

    Reason given in the registry

    “Study paused per IRB request.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Feb 2026.

    Run by
    University of Southern California
    Registry record
    NCT07429591
  28. Terminated

    Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

    Reason given in the registry

    “Sponsor decision to terminate study early. Decision not based on safety concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Feb 2026.

    Ended
    Dec 2025
    Phase
    Phase 1
    Run by
    Ionis Pharmaceuticals, Inc.
    Registry record
    NCT06673069
  29. Withdrawn

    Dementia Prevention Internet-Based Intervention: Randomized Controlled Trial and Knowledge Translation

    Reason given in the registry

    “Study did not receive funding.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Feb 2026.

    Ended
    Jan 2026
    Run by
    McMaster University
    Registry record
    NCT06911047
  30. Terminated

    Extension Study of Participants From SPG302-ALZ-101

    Reason given in the registry

    “patients treated on compassionate use program”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Dec 2025.

    Ended
    Oct 2025
    Phase
    Phase 2
    Run by
    Spinogenix
    Registry record
    NCT06833281

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.